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Abstract
Background: Despite increasingly frequent bacterial resistance to antibiotics, antibacterial innovation is rare. Ketolides
constitute one of the very few new antibiotic classes active against Streptococcus pneumoniae developed during the last 25
years. Their mechanism of action resembles that of macrolides, but they are unaffected by common resistance mechanisms.
However, cross-resistance to ketolides has been observed in some macrolide-resistant strains. We examined how new
antibiotic exposure may affect overall pneumococcal resistance patterns in the population. The aims of this study were to
assess the potential dissemination of newly emerged resistances and to control the selection of strains already
multiresistant to existing antimicrobials.
Methodology/Principal Findings: We developed an age-structured population model for S. pneumoniae transmission in a
human community exposed to heptavalent vaccine, and b-lactams, macrolides and ketolides. The dynamics of intra-
individual selection of resistant strains under antibiotic exposure and interindividual transmission were simulated, with
antibiotic-specific resistance mechanisms defining the path to co-resistances and cross-resistances, and parameters
concerning the French situation. Results of this simulation study suggest that new antibiotic consumption could markedly
slow the diffusion of multiresistant strains. Wider use was associated with slower progression of multiresistance. When
ketolides were prescribed to all ages, resistance to them reached 10% after .15 years, while it took .40 years when they
were prescribed only to adults. In the scenario according to which new antibiotics totally replaced former antimicrobials, the
b-lactam resistance rate was limited at 70%.
Conclusions: In a context of widespread vaccination and rational use of antibiotics, innovative antibiotic, prescribed to all
age groups, may have an added impact on multiresistant-strain dissemination in the population.
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Introduction
Bacterial resistance to antibiotics has become a major public
health problem worldwide and direct consequences are now being
documented in terms of increased morbidity, mortality and
hospitalization costs [1–4]. Minimizing selection of pathogenic
bacteria that have acquired mechanisms of resistance to antibiotics
has become a top priority of international public health
authorities. Streptococcus pneumoniae is a major cause of morbidity
and mortality worldwide [5], and the main cause of community-
acquired respiratory tract infections, e.g., otitis media, sinusitis and
pneumonia. It is also a major pathogen responsible for invasive
disease, like septicemia and meningitis.
In recent decades, antibiotic-resistant and multiresistant S.
pneumoniae strains have spread throughout the community. In some
European countries, such as France or Spain, penicillin non-
susceptible strains represent .50% of all pneumococci, as do
macrolide-resistant strains [6]. Multiresistance is also being
observed more and more frequently. Despite this increased
antibiotic resistance, very few new antibacterial classes have been
developed by pharmaceutical companies over the last few decades
[7].
The 7-valent pneumococcal conjugate vaccine (PCV7) mark-
edly decreased resistant S. pneumoniae infections [8,9], but recent
observations suggest the emergence of non-vaccine serotypes with
high levels of resistance to all approved antibiotics [10].
PLoS ONE | www.plosone.org 1 May 2008 | Volume 3 | Issue 5 | e2089Since antibiotic exposure is the main driving force behind the
selection of strains harboring resistance to current drugs, a new
class of antibiotic, without preexisting resistant strains, could help
control the selection of resistance to older drugs, but emergence of
new resistances to these new antibiotics is to be expected. The aims
of this study were to examine that hypothesis using mathematical
modeling, and to optimize strategies of new compound use by
maximizing the time until emergence of new resistances and
controlling the selection of resistant strains to preexisting
antimicrobials.
This investigation was specifically conducted on ketolides, one
of the newest antibiotic classes marketed for community-acquired
respiratory tract infections.
Materials and Methods
We built a compartmental model of the transmission of S.
pneumoniae in the French community under multiple antibiotic
exposures. The model was specific to different mechanisms of
resistance and the natural history of pneumococcal colonization.
Using this model, we explored the diffusion of colonizing resistant
and multiresistant pneumococci, according to antibiotic exposure.
The objectives were to anticipate trends in new ketolide-resistance
selection and multiresistance selection. First, we describe the
model structure, then detail the parameters and, finally, present
the scenarios that were simulated.
Model Description
The model developed herein takes into account 3 different
antimicrobial classes (P: penicillin as an example of b-lactams, M:
macrolides and K: ketolides), PCV7, and pertinent parameters
concerning the French situation taken from the literature (Table 1).
To reproduce the selection and spread of resistant bacteria in
the community through interindividual transmission of S.
pneumoniae strains, the population was divided into several groups
or compartments. Compartments were structured with respect to
age, vaccination status, colonization and antibiotic exposure
(Figure 1). To take into account differences according to the
hosts’ ages, the population was divided into 3 age classes
corresponding to young children (0–2 years), older children (2–
15 years) and adults (.15 years). Hosts entered the population at
birth as young children non-carriers. Mortality rates were defined
for each class. We assumed that a fraction of young children was
vaccinated each year. Vaccinated individuals were protected
against carriage of serotypes included in PCV7, but not against
carriage of serotypes not included in it.
Independently of their carriage status, individuals could be
exposed to b-lactams (penicillin) and macrolides, as they are the
main antibiotic classes prescribed in France [11]; and ketolides as
the antibiotic innovation. We assumed that individuals were
exposed to only 1 antibiotic class at a time. Because prescription
frequencies depend on age and antibiotic classes, the matrix a[i,j]
describes the rates of exposure as a function of age i and antibiotic
class j. Under antibiotic exposure, strains with higher levels of
resistance can emerge through genetic events and be selected,
thereby replacing the strains originally harbored in the host in
whom colonization had not been eliminated.
Parameters
Parameter values are listed in table 1. We used demographic
data from the French National Institute of Statistics and
Economical Studies (INSEE) [12] for the birth rate (m0) and
mortality rates of each age class (m1, m2, m3). Pneumococcal
colonization was defined as decreasing with age [13,14]: 50% in
young children (,2 years old), 30% in older children (2–15 years
old) and 10% in adults (.15 years old). The contact matrix was
considered to be symmetric. Values of the age-specific contact
rates b[i,j] were numerically calibrated so that the prevalence of
overall carriage at the model equilibrium corresponded to that
observed in the French population.
In the absence of antibiotic exposure, natural immunity was
defined as inducing carriage clearance in colonized individuals,
according to their age: on average, 2 months for young children
Table 1. List of model parameters and their values.
Parameter Variable Mean value
Birth rate m0 0.000250 week
21
Death rate of
Young children (,2 years) m1 0.000112 week
21
Older children (2–15 years) m2 0.000047 week
21
Adults (.15 years) m3 0.000295 week
21
Infectious contact rate within
Young children b11 0.9 week
21person
21
Older children b22 0.7 week
21 person
21
Adults b33 0.3 week
21 person
21
Infectious contact rate between
Young and older children b12 0.68 week
21 person
21
Young children and adults b13 0.68 week
21 person
21
Older children and adults b23 0.68 week
21 person
21
Frequency of antibiotic exposure in 2002
among
Young children [a00, a10] [0.046, 0.0065]
week
21
Older children [a01, a11] [0.018, 0.0042]
week
21
Adults [a02, a12] [0.0086, 0.0044]
week
21
Vaccination rate of young children
(,2 years)
v 30% (2004)–90%
(2007)
Duration of vaccine immunity dv 13 years
Probability of non-decolonization after
4 days of
Penicillin for carriers of SP,I P and RP
pneumococci
[s0, s1, s2] [0.05, 0.35, 0.6]
Macrolide for carriers of SM and RM
pneumococci
[s3, s4] [0.03, 0.62]
Ketolide for carriers of SK and RK
pneumococci
[s5, s6] [0.03, 0.62]
Probability of incremental resistance of
b-Lactams, SRI, SRRa n dI RR[ p0, p1, p2] [0.0125, 1.5610
26,
5610
25]
Macrolides, SRR p3 0.011
Ketolides, SRR p4 0.01
Time until treatment acts 1/n 4 days
Duration of antibiotic exposure 1/c 8 days
Duration of colonization of
Young children 1/l1 9 weeks
Older children 1/l2 4 weeks
Adults 1/l3 2 weeks
NOTE. S, susceptible; I, intermediate; R, resistant.
doi:10.1371/journal.pone.0002089.t001
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l3) [15–18].
Pneumococcal conjugate vaccine. PCV7 protects against
both invasive disease and pharyngeal colonization [8], and has
been recommended for young children in several countries [19–
21]. In France, about 30% of children ,2 years old,
corresponding to all children in day care, were vaccinated each
year before 2006. In 2006, recommendations were extended to
systematic vaccination of all children ,2 years old [22]. Previously
developed models, describing the effect of vaccination on
pneumococcal carriage and resistance, predicted replacement of
serotypes included in the vaccine by non-vaccine serotypes
[23,24]. In our model, young children were vaccinated at rate v.
Vaccinated children were assumed to have received 4 doses of
PCV7 (including 1 booster dose), and thus to be fully immunized
against serotypes included in PCV7. We assumed progressively
increasing vaccination coverage between 2002 and 2004 from no-
vaccination to vaccination of 30% of young children. After 2007,
date of systematic vaccination of young children, we considered
young children’s vaccine coverage to be 90%. Vaccine immunity
(dv) was supposed to last throughout childhood.
Antibiotic-exposure parameters. We considered the global
antibiotic consumption regardless of indication of the drugs. We
used annual global data published by the French National Health
Insurance Agencies (CNAM–TS, CANAM) [25], covering .95%
of the population, to evaluate prescription frequencies for the 3
antibiotic classes of interest for each age class. Consumption varied
with age: children ,5 years old had high rates of exposure, while
prescriptions were quite low for adults. To be consistent with the
objective of overall antibiotic-use reduction in France, a
progressive and homogeneous decrease of global antibiotic
exposure was assumed for all age groups (reaching 25%, 20%
and 10% reductions over a 5-year period in young children, older
children and adults, respectively). We investigated scenarios of
ketolide exposure from the current status to their total replacement
of old antibiotic classes, as developed below in detail.
Treatment duration (1/c) was assumed to be the same
regardless of the antibiotic prescribed (8 days). We considered
that the antibiotic effect on colonization (s) started after an
average of 4 days of exposure (1/n) and that it depended on the
colonizing strain’s level of susceptibility (see below).
Antibiotic resistance. Three stages of S. pneumoniae penicillin-
susceptibility, corresponding to increasing minimum inhibitory
concentrations (MIC), were modeled [26]: susceptible (SP),
intermediate (IP), and resistant (RP), for strains with respective
MIC,0.125, 0.125#MIC,2 and MIC.2 mg/mL. Furthermore,
Figure 1: Schematized model structure. The model is structured according to age and antibiotic exposure: 3 age groups (,2, 2–15, .15 years)
and 4 types of exposure (none, penicillin, macrolides, ketolides). (A) For each age/antibiotic exposure combination, 3 possible carriage (C) statuses are
described: absence of carriage (NC) and carriage of either the vaccine-type (CV) or non-vaccine-type (CNV) pneumococcal strains. For vaccinated
individuals, only 2 carriage statuses exist: NC and CNV.( B) Model substructure. More precisely, colonized individuals are divided into 9
subcompartments corresponding to carriage of a pneumococcal strain with one of the 9 possible levels of resistance, ranging from susceptible to the
3 antibiotic classes (SSS) to resistant to all of them (RRR), and all possible susceptibility-level combinations in-between. The subscripts correspond to
susceptible (S), intermediate (I) or resistant (R) to b-lactams (P), macrolides (M) and ketolides (K). Because of the cross-resistance hypothesis, ketolide-
resistant strains are always resistant to macrolides.
doi:10.1371/journal.pone.0002089.g001
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PLoS ONE | www.plosone.org 3 May 2008 | Volume 3 | Issue 5 | e2089since S. pneumoniae’s macrolide-resistance acquisition by ribosomal
structure modification can be viewed as an on/off mechanism [27],
corresponding to resistant/susceptible bacteria, macrolide-
susceptible and -resistant (SM and RM) strains were considered.
Ketolides have a mechanism of action similar to that of macrolides
[28], but RM strains are generally susceptible to ketolides (SK).
Importantly, the few documented examples of ketolide-resistant
(RK) strains concerned those already resistant to macrolides. That
observation suggests that ketolide resistance is conditioned by
previous resistance to macrolides (cross-resistance) [29–31].
Therefore, macrolide resistance was considered to be a prerequi-
site for the later emergence of ketolide resistance, which was
ascribed to all strains already RM. Consequently, all RK strains
colonizing individuals in the model were also RM.
Emergence of resistance or an increase of its level was possible
in colonized individuals exposed to antibiotics. Resistance levels
evolved independently for penicillin and macrolides. Their rates of
increased resistance (SPRIP,S PRRP,I PRRP and SMRRM) were
numerically estimated so that simulation results agreed with the
observed historical trends (before 1992) of emergence and diffusion
of RP and RM strains (pi). For ketolides, the same rates as those
estimated for macrolides were used.
Multiresistance. Because pneumococcal strains can
combine resistances to different antibiotics, 2 types of
multiresistant strains were included and evaluated in the model:
penicillin–macrolide-resistant strains (denoted: (IP/RP)+RM) and
penicillin–macrolide–ketolide-resistant strains ((IP/RP)+RM+RK).
Macrolide–ketolide-resistant (RM+RK) but penicillin-susceptible
(SP) strains were not considered multiresistant strains, because of
the macrolide–ketolide cross-resistance.
Model Fitting and Simulations
To validate model predictions, we used historical data on
antibiotic consumption in France [32], and compared simulation
results with pneumococcal resistance and multiresistance rates
from 1992 to 1997 reported by the French National Center for
Pneumococci (CNRP), which coordinates the national surveillance
system of pneumococcal infections [33].
Initialization. We initialized the model with a population in
which resistant pneumococcal rates were equivalent to the 2002
French situation [33] with .50% of IP/RP strains, .55% of RM
strains and 0.1% preexisting RK strains [34–37].
Scenarios. We investigated the impact of ketolide exposure
by simulating 3 scenarios (Figure 2). The first, Baseline,
corresponded to no ketolide-use, i.e. the French situation before
2005. The second scenario, K-Adults, consisted of replacing 25%,
50%, 75% or 100% of adult prescriptions with ketolides. The last
scenario, K-All, consisted of replacing 25%, 50%, 75% or 100% of
prescriptions with ketolides in all age groups.
To study RK emergence and selection, we estimated the times
required for 1% or 10% of strains colonizing the population to
become RK. Furthermore, we simulated the expected dynamics of
multiresistance diffusion over the next 50 years, defined as
resistance to at least penicillin and macrolides ((IP/RP)+RM),
according to the scenarios.
Sensitivity analysis. A sensitivity analysis was undertaken to
evaluate the dependence of model predictions (percentages of RK
and multiresistant strains in the colonized population) on small
variations of all input parameters (such as the contact matrix,
antibiotic exposure levels, etc.). The parameters were allowed to
vary within a range of their possible values. Latin Hypercube
Sampling (LHS) was used and partial rank correlation coefficients
(PRCC) were computed for all parameters [38].
Results
The historical time course of macrolide resistance, penicillin
resistance and penicillin-macrolide multiresistance from 1992 to
1997 were well reproduced by model simulations (Figure 3). In a
previous study using data from the United States, we showed that
the simulated decrease over the first 3 years of mass vaccination
was consistent in magnitude with the observed data, in terms of
invasive disease incidence and in terms of RP [24].
Emergence of ketolide-resistant strains. In scenario K-
Adults, ketolides were prescribed only to adults. Times to
emergence of 1% and 10% RK pneumococcal strains in the
population are presented in figure 4A for different levels of ketolide
exposure. For up to 50% of ketolide use among adults, the mean
emergence time of 10% RK exceeded 50 years. Under the
hypothesis that ketolides effectively replaced high rate of the
preexisting antimicrobials in total adult antibiotic consumption, it
still took .35 years to reach 10% RK.
When ketolides were prescribed to all ages (scenario K-All),
times before RK emergence were shorter (Figure 4B). When
ketolides replaced at least 20% of all preexisting antibiotic
consumption, it took ,40 years to reach 10% RK, whereas for
quasi-total (90%) ketolide replacement of former antibiotics,
simulations predicted that 10% RK could be reached within a
dozen years.
Dynamics of multiresistant strains. When the new drugs
were prescribed only to adults (scenario K-Adults, figure 5A), the
dissemination of (IP/RP)+RM multiresistant strains was barely
slowed by ketolide use over the first few years. However, after RK
emergence and selection, the diffusion of strains resistant to P, M
and K ((IP/RP)+RM+RK) was accelerated with increased ketolide
use, as a consequence of the co-selection of RM+RK strains under
ketolide exposure, owing to macrolide–ketolide cross-resistance.
Twenty years after RK emergence and its selection in the
population, no significant differences in the frequencies of
carriage of multiresistant pneumococcal strains remained
between the scenario using ketolides (K-Adults) and the one not
using them (Baseline).
When ketolide prescriptions were extended to the entire
population (scenario K-All, figure 5B), the dissemination of (IP/
RP)+RM strains differed markedly according to the prescription
level. The higher the ketolide-prescription rate, the lower the
initial diffusion of (IP/RP)+RM strains, but the emergence of (IP/
RP)+RM+RK multiresistant strains no longer slowed the resistance
rise and even enhanced it. K-All (IP/RP)+RM+RK multiresistance
appeared more rapidly than in K-Adults, and quickly encom-
passed all resistant strains. Importantly, when ketolides replaced
.50% of current antibiotics, the simulations showed 2-step
dynamics: first, a strong deceleration of (IP/RP)+RM strain
dissemination; second, an acceleration, increasing with the rise
of the replacement rate. In the extreme case in which ketolides
totally replaced current antibiotics (100%), the maximum
multiresistance level was reached after only 20 years. It should
be noted that, when ketolides totally replaced preexisting
antibiotics, the model predicted that multiresistant-strain diffusion
would cease at ,70%, maintaining a reservoir of SP strains.
Sensitivity analysis. The most significantly sensitive
parameters are listed in table 2. Concerning RK and
multiresistance rate outcomes, the model was particularly
sensitive to the frequencies and duration of antibiotic exposure:
when either increased, the proportion of resistant strains increased.
Moreover, the model was sensitive to the average time until
treatment acts: when it decreased, resistance increased (PRCC
,0.6). Furthermore, the multiresistance rate was positively
Modeling New Drug’s Impact
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antibiotic exposure in all age groups. Transmission rates between
and within age-classes did not significantly influence the global
resistance rates.
Discussion
The results of this simulation study suggest that new
antimicrobial use could markedly slow the diffusion of (IP/
RP)+RM multiresistant strains. During the initial period after
ketolide introduction, their wider use was associated with a slower
progression of multiresistance. The model predicted it would take
.15 years to reach 10% of RK in the population when the new
drug was prescribed to all ages, and .40 years, when it was
prescribed only to adults. In all cases, except when ketolides
replaced all other drugs in the community, bacterial resistance
increased, eventually reaching high rates of strains multiresistant to
the 3 drugs [(IP/RP)+RM+RK], due to co-selection of RM+RK
strains under ketolide exposure. When all drugs but ketolides were
discontinued, the resistance to b-lactams was contained at ,70%.
Obviously, this unrealistic strategy raises contradictory economic
questions: should new drugs be developed in order to preserve old
drug efficacy?
Current trends in Streptococcus pneumoniae epidemiology are difficult
to anticipate: first, the epidemiological situation is complex because
of multiresistant strains and multi-exposures to antibiotics; second,
important changes have occurred recently with the availability and
wide use of PCV7 and the measures undertaken to reduce antibiotic
prescriptions. In the past, models helped to analyze probable
changes, predicting changes in serotypes after vaccine use [23,39],
investigating the associations between antibiotic use and RP [40] or
explaining why b-lactam resistance presented a bimodal shape [41].
Here, using a model taking these recent changes into account, we
investigated how the use of a new antimicrobial can modify the
resistance patterns in the community.
As non-vaccine strains are currently less resistant to macrolides
[9,42], immunization may delay the occurrence of RK. For that
reason, and also because wide vaccine coverage might select for
non-vaccine–serotype multiresistant stains [10], PCV7 was
included in this study. No precise estimate exists for the duration
Figure 2: Description of epidemiological pertinent facts and scenarios, showing how parameters of antibiotic-exposure rates (P,
penicillin; M, macrolides; K, ketolides) and PCV7 immunization rates evolved in the simulations. (A) Scenarios of ketolide introduction.
Baseline: K are never prescribed; K-Adults: K are prescribed only to adults, to replace P and M; K-All: K are prescribed to all individuals, to replace P and
M. In the two K-scenarios, the level of replacement varies from 0% to 100%. (B) Timeline of relevant epidemiological changes included in the model.
doi:10.1371/journal.pone.0002089.g002
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only a few years ago. In our model, we assumed that PCV7-
induced immunity would last throughout childhood. A shorter
(longer) duration of immunity would be nearly equivalent to
predictions of immunizing a smaller (greater) portion of young
children.
The model and results presented here are specific to the
introduction of ketolides into a population exposed to high rates of
penicillin and macrolide use.
First, the study was restricted to penicillin, macrolides and
ketolides, excluding other antibiotics, such as quinolones or
cyclines. In most countries, as in France, b-lactams and macrolides
are the most frequently prescribed antimicrobial classes. More-
over, S. pneumoniae resistance to them has reached high percentages
in several Western countries and become a major public health
concern [11]. In contrast, fluoroquinolone and cycline antibiotic
resistances remain a quite low [35] and are not, at this time, a
worrisome problem in terms of clinical failure in Europe and the
US. For those reasons, we focused on the control of RP and RM
and multiresistance. Considering other antibiotics and S. pneumo-
niae resistance to them in the model would have had little to no
effect on the predicted changes in the main resistance patterns in
the community in the near future.
Second, we described the pathway to RK based on current
observations: RK can be developed only in RM strains. This
assumption effectively limits the selection for RK to strains already
RM, so that progression to resistance is slower than in a setting in
which resistance to the new drug would appear independently of
others. The evolution of resistance to such a drug could easily be
analyzed in the same setting: it is expected that, in the same
context, the emergence of a new resistance would be faster but the
selection slower.
Third, the efflux-pump resistance mechanism, which endows S.
pneumoniae with low-level RM, was not considered in the model.
Indeed, for macrolides, the model developed herein was based on
the French situation. In France, the vast majority of RM isolates
have acquired a ribosomal modification resistance mechanism
[35]. Moreover, the efflux-pump mechanism does not impair
ketolide activity, while the ribosomal modification mechanism has
marked impact in terms of selective pressure on both RM and RK.
Consequently, in the French context, adding the possibility of 3
Figure 3: Dynamics of antibiotic-resistant and -multiresistant S.
pneumoniae strains, 1992–1997: observed (dashed line) and
predicted (black line) percentages. RM and IP/RP lines correspond,
respectively, to macrolide and b-lactam–resistance rates. (IP/RP)+RM
represents percentages of b-lactam- and macrolide-multiresistant S.
pneumoniae strains.
doi:10.1371/journal.pone.0002089.g003
Figure 4: Time to emergence of ketolide-resistant S. pneumo-
niae. Times to reach 1% or 10% resistant strains among colonized
individuals as a function of the rate of ketolide prescriptions replacing
penicillin and macrolides in adults (A) or the entire population (B) are
shown. Three ketolide-prescription levels are depicted: low, medium
and high replacement rates of total antibiotic consumption. For these
simulations, times were computed using p4=0.01 as the probability of
ketolide-resistance emergence in strains. The T-bars represent the lower
and upper prediction intervals, corresponding to p4=0.1 and 0.001,
respectively.
doi:10.1371/journal.pone.0002089.g004
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resistant, and highly resistant) would have limited influence on the
predictions.
Fourth, the model could also be used in a setting with lower
exposure to penicillins and macrolides. In that case, initial RP and
RM rates would also be lower, and the emergence and selection of
new resistances would be expected to slow, and the impact on
multiresistance trends of a new antibiotic to be delayed.
In the scenarios, we assumed a sudden replacement of part of
current antibiotics by the innovative agent, while it could be more
progressive over time in real life. The simulated situation
constitutes a worst-case scenario for the selection of RK.
Figure 5: Impact of ketolide prescriptions on the emergence and selection of multiresistant S. pneumoniae. Evolutions of multiresistant-
strain carriage as a function of time are shown. These simulations were carried out according to the 2 scenarios of K prescriptions: (A) K-Adults:
ketolides were only used by adults after 2007, with 4 different replacement rates of adult antibiotic prescriptions: 0% (N); 25% (o); 75% (+); and 100%
(2). (B) K-All: K prescriptions were extended to the entire population (including children) with the same replacement rates as previously.
doi:10.1371/journal.pone.0002089.g005
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practice, but at most by the length of the progressive replacement
period. Likewise all other kinetic steps would occur later.
The model uses several simplifications regarding the diversity of
S. pneumoniae ecology and the results presented should be
interpreted in the context of the following 3 limitations. First,
our simulation did not examine the time required for pneumococci
to acquire a new RK mechanism, but rather that needed to reach
an epidemiologically meaningful resistance level in the population.
At present, few RK strains exist in the community [37]; therefore,
we focused here on the time needed to select and spread these
resistant strains depending on the different drug-use scenarios
(figure 4). Second, the possibility of colonization (and transmission)
with several strains having different resistance patterns was not
considered in this study. Lastly, serotypes were grouped according
to their inclusion in the PCV7 rather than individually modeled. A
higher level of details could be achieved, for instance using
serotype-specific duration of carriage or immunity to S. pneumoniae
[43]. However, the main conclusions regarding the impact of
ketolides on the emergence and progression of multiresistance
would not be affected by these latter choices.
In our sensitivity analysis, the parameters that caused the
largest changes in results were: the frequencies and duration of
antibiotic exposure (when they increased, the proportion of
resistant strains increased); and the mean time until treatment
acts (when was shorter, the mean time for resistance selection
took longer and resistance became more prevalent). When
antibiotics eliminate sensitive strains more quickly, the opportu-
nity for sensitive strains to become resistant is decreased;
however, once resistance has emerged, resistant strains have a
stronger selective advantage.
It has been suggested [44,45] that the transmissibility of resistant
strains could be lower than that of susceptible strains because
resistance acquisition could imply a fitness cost. We did not
include any fitness difference in our model. In terms of prediction,
we would expect that introducing fitness cost for resistant strains,
which increases with multiresistance, would delay the second-wind
rise of multiresistance in non-vaccine strains. To date, however,
biological evidence on this possibility at the human level is sorely
lacking [46].
Recently, the US Food and Drug Administration approved a
new label for ketolides, removing specific indications (acute
bacterial sinusitis and acute exacerbation of chronic bronchitis)
and adding warnings and contraindications [47]. This new
labeling was incited by a rare hepatitis linked to ketolide use
[48,49]. Consequently, the ketolide-use benefit predicted by the
model should be balanced by the incidence of severe adverse
effects. At this point, precise quantification of the costs, morbidity
and mortality associated with pneumococcal antibiotic resistance
becomes urgent [50–52]. Modeling, complemented with such
data, should enable estimation of benefits and risks and should
become a real support for public health decision-making.
Today, the only available ketolide drug, telithromycin, is
approved for use only in adults, although children represent a
large portion of antibiotic users. However, other new ketolide-class
antibiotics, with the same activity as telithromycin, like cethro-
mycin, are being developed [53,54] and could be prescribed to
children in the future. In that context, the model predictions could
show how the use of such an antibiotic innovation could impact
the global pattern of resistance, at the population level.
We want to underline that the main pathways for resistance
control remain the global reduction of antibiotic consumption,
generalized PCV7 immunization of young children, and cautious
and appropriate use of antibiotics at the individual level. While the
results of this study emphasize the potential benefits of a partial
replacement of currently used antibiotics by a new antibiotic class,
our conclusion is not to encourage the wide use of ketolides but to
demonstrate that innovation could be a complementary way to
reduce antibacterial resistance at the community level.
According to our model, restriction of ketolide prescriptions to
adults, even at a high replacement rate, would have a limited effect
on the global resistance pattern and would mainly lead to clinical
success. When extended to children, ketolide use would be
associated with only a short-term positive effect. Using a model
that included age-structured population and specific resistance and
multiresistance mechanisms (cross-resistance and co-resistances),
our findings are in agreement with the situation described by
Wang and Lipsitch [55]: upgrading antibiotic use within a class
(fluoroquinolones vs macrolides/ketolides here) would lead to a
trade-off between high prevalence of highly multiresistant strains
and successful treatment. Facing the choice between enhancing
therapeutic success and controlling global resistance, these models
can be useful for decision-makers.
In conclusion, our simulation results predict that, in a
population with widespread use of PCV7 and rational use of
antibiotics, antibiotic innovation, prescribed to all age groups,
particularly children, could have an added impact on multiresis-
tance rates: the more the new drug is prescribed, the slower
multiresistance would diffuse. However, at the same time, the
more this new drug is used, the faster new multiresistant
pneumococcal strains ((IP/RP)+RM+RK strains here) would be
selected.
Paradoxical as it may seem, to prevent community-wide
dissemination of strains simultaneously resistant to all available
antibiotics, the optimal solution for the next 20-years, would be to
Table 2. Sensitivity analysis of the frequency of ketolide-
resistant or multiresistant strains in the colonized population.
Parameter Variable PRCC
a
Frequency of ketolide-resistant strains as output
Frequency of ketolide exposure in adults (.15 years) a33 0.3
(Duration of antibiotic exposure)
21 c 20.7
(Time until treatment acts)
21 n 0.6
Probability of SRR incremental resistance of
macrolide/ketolide
p4 0.22
Frequency of multiresistant strains as output
Frequency of exposure
b-Lactam in children (2–15 years) a12 0.1
b-Lactam in adults (.15 years) a13 0.2
Ketolide in young children (,2 years) a31 0.1
Macrolide in adults (.15 years) a23 0.1
(Duration of antibiotic exposure)
21 c 20.6
(Duration of colonization in adults)
21 l3 0.1
(Time until treatment acts)
21 n 0.6
Vaccination rate v 20.2
aPartial rank correlation coefficient (PRCC) indicates the degree of monotonicity
between a specific input variable and a particular outcome variable. The sign
of the PRCC indicates the qualitative relationship between input and output
variables. The magnitude indicates the importance of uncertainty in estimating
the value of the input variable in contributing to the imprecision in predicting
the value of the outcome variable.
doi:10.1371/journal.pone.0002089.t002
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for which non-resistant strains still exist.
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